AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29156903 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative radiotherapy (single 8 Gy radiation treatment)
Number of subjects: 298
Study 26307050 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracytoplasmic morphologically selected sperm injection (IMSI)
Number of subjects: 121
Study 26307050 — intervention group
Group type: COMPARATOR
Intervention: Conventional intracytoplasmic sperm injection (cICSI)
Number of subjects: 121
Study 23810874 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified group treated with RAS antagonists and beta-blockers
Number of subjects: 300
Study 23810874 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified group
Number of subjects: 300
Study 23810874 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 300
Study 21184869 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol plus fentanyl (0.25 mg/kg plus 50 μg intravenously)
Number of subjects: 210
Study 21184869 — intervention group
Group type: COMPARATOR
Intervention: Midazolam plus fentanyl (0.05 mg/kg plus 50 μg intravenously)
Number of subjects: 210
Study 20149045 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low dose oral contraceptives (100 microg levonorgestrel + 20 microg ethinyl estradiol)
Number of subjects: 186
Study 20149045 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose oral contraceptives (150 microg desogestrel + 30 microg ethinyl estradiol)
Number of subjects: 186
Study 20149045 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186
Study 20149045 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low dose oral contraceptives
Number of subjects: 186
Study 20149045 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose oral contraceptives
Number of subjects: 186
Study 17530986 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO-PRO supplement (6.2% carbohydrate and 1.5% protein)
Number of subjects: 34
Study 17530986 — intervention group
Group type: COMPARATOR
Intervention: Placebo (electrolyte and artificial sweetener beverage)
Number of subjects: 34
Study 17530986 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 17530986 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO-PRO supplement
Number of subjects: 34
Study 16488469 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized educational leaflets and post-discharge telephone counseling regarding fall prevention strategies
Number of subjects: 102
Study 16488469 — intervention group
Group type: COMPARATOR
Intervention: Attention-controls
Number of subjects: 102
Study 12556774 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sphincterotomy
Number of subjects: 282
Study 12556774 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic papillary balloon dilatation
Number of subjects: 282
Study 10516536 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean-style restricted diet
Number of subjects: 16
Study 8542862 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (1.5% end‐tidal, 0.73 MAC) with N2O 58% (0.58 MAC)
Number of subjects: 80
Study 8542862 — intervention group
Group type: COMPARATOR
Intervention: Enflurane (1.2% end‐tidal, 0.7 MAC) with N2O 57% (0.57 MAC)
Number of subjects: 80
Study 8542862 — intervention group
Group type: EXPERIMENTAL
Intervention: Both sevoflurane and enflurane
Number of subjects: 80
Study 8542862 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane anaesthesia
Number of subjects: 80
Study 1773716 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal insulin (INI) 1 U/kg
Number of subjects: 11
Study 1773716 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 6923833 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis with mezlocillin and oxacillin (4 and 2 grams) every 8 hours, starting after intubation.
Number of subjects: 297
Study 6923833 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prophylaxis).
Number of subjects: 297
Study 30455187 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA (100 mg)
Number of subjects: 20
Study 30455187 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30455187 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA
Number of subjects: 20
Study 28606620 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumacaftor and ivacaftor (200 mg lumacaftor and 250 mg ivacaftor every 12 hours for 24 weeks)
Number of subjects: 206
Study 28606620 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumacaftor and ivacaftor
Number of subjects: 206
Study 28606620 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206
Study 25809853 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat spread with added plant sterols (3 g/d)
Number of subjects: 240
Study 25809853 — intervention group
Group type: COMPARATOR
Intervention: Control (low-fat spread without added plant sterols)
Number of subjects: 240
Study 23274956 — intervention group
Group type: COMPARATOR
Intervention: 3 months of prednisolone followed by 3 months of placebo (n=74)
Number of subjects: 150
Study 23274956 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 months of prednisolone (n=76)
Number of subjects: 150
Study 22232847 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of digoxin
Number of subjects: 20
Study 22232847 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of digoxin
Number of subjects: 20
Study 19695711 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 126
Study 19695711 — intervention group
Group type: COMPARATOR
Intervention: Venlafaxine
Number of subjects: 126
Study 16892797 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic hip screw (DHS, group A, n=42)
Number of subjects: 88
Study 16892797 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomical proximal femur bone plate (group B, n=23)
Number of subjects: 88
Study 16892797 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal femoral nail (PFN, group C, n=8)
Number of subjects: 88
Study 16892797 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic condylar screw (DCS, group D, n=15)
Number of subjects: 88
Study 16892797 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 88
Study 12942977 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex tones in cosine phase (CPH)
Number of subjects: 0
Study 12942977 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex tones in random phase (RPH)
Number of subjects: 0
Study 12942977 — intervention group
Group type: COMPARATOR
Intervention: Gaussian noise
Number of subjects: 0
Study 12942977 — intervention group
Group type: EXPERIMENTAL
Intervention: CPH tone as forward masker
Number of subjects: 0
Study 12942977 — intervention group
Group type: EXPERIMENTAL
Intervention: RPH tone as forward masker
Number of subjects: 0
Study 12942977 — intervention group
Group type: COMPARATOR
Intervention: Noise as forward masker
Number of subjects: 0
Study 10631214 — intervention group
Group type: COMPARATOR
Intervention: Placebo inhaler bid + bolus placebo
Number of subjects: 12
Study 10631214 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol Turbuhaler 24 microg metered dosage bid (delivered dosage 18 microg bid) + placebo
Number of subjects: 12
Study 10631214 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 24 microg bid + bolus IV hydrocortisone, 200 mg
Number of subjects: 12
Study 10631214 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 24 microg bid + bolus inhaled budesonide, 1,600 microg
Number of subjects: 12
Study 10631214 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 10631214 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol alone
Number of subjects: 12
Study 10631214 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol + hydrocortisone
Number of subjects: 12
Study 10631214 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol + budesonide
Number of subjects: 12
Study 9021907 — intervention group
Group type: EXPERIMENTAL
Intervention: MgSO4 infusion
Number of subjects: 200
Study 9021907 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment or digoxin for specific cases)
Number of subjects: 200
Study 1411622 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin (starting dose of 320 mg/m2)
Number of subjects: 418
Study 1411622 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide/carboplatin
Number of subjects: 418
Study 1411622 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide/cisplatin
Number of subjects: 418
Study 6093240 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime (short course)
Number of subjects: 179
Study 6093240 — intervention group
Group type: COMPARATOR
Intervention: Control (no antibiotics)
Number of subjects: 179
Study 29368545 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking (10 minutes)
Number of subjects: 110
Study 29368545 — intervention group
Group type: EXPERIMENTAL
Intervention: Meditation (10 minutes)
Number of subjects: 110
Study 29368545 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking then Meditation (10 minutes each)
Number of subjects: 110
Study 29368545 — intervention group
Group type: EXPERIMENTAL
Intervention: Meditation then Walking (10 minutes each)
Number of subjects: 110
Study 29368545 — intervention group
Group type: COMPARATOR
Intervention: Sitting (inactive control)
Number of subjects: 110
Study 30122326 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional yoga breathing with intermittent breath holding for 20 minutes, 8 weeks duration
Number of subjects: 116
Study 30122326 — intervention group
Group type: COMPARATOR
Intervention: Regular yoga practice (control group)
Number of subjects: 116
Study 27470232 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled milrinone (iMil)
Number of subjects: 124
Study 27470232 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 25267274 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary prevention ICD patients with EPS (group 1)
Number of subjects: 470
Study 25267274 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary prevention ICD patients without EPS (group 2)
Number of subjects: 470
Study 25267274 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary prevention ICD patients (group 3)
Number of subjects: 470
Study 25267274 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary prevention ICD patients with positive EPS result
Number of subjects: 470
Study 25267274 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary prevention ICD patients with negative EPS result
Number of subjects: 470
Study 25267274 — intervention group
Group type: COMPARATOR
Intervention: EPS-guided primary prevention ICD patients
Number of subjects: 470
Study 22196566 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 weekly 30-min massages
Number of subjects: 50
Study 22196566 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 weekly 30-min massages
Number of subjects: 50
Study 22196566 — intervention group
Group type: COMPARATOR
Intervention: Control group (no massage therapy)
Number of subjects: 50
Study 20143202 — intervention group
Group type: EXPERIMENTAL
Intervention: Humor therapy group (experimental group)
Number of subjects: 90
Study 20143202 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific treatment)
Number of subjects: 90
Study 18056902 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin (500 mg 3 times per day for 7 days)
Number of subjects: 240
Study 18056902 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Budesonide (200 mug in each nostril once per day for 10 days)
Number of subjects: 240
Study 18056902 — intervention group
Group type: COMPARATOR
Intervention: No Amoxicillin (placebo)
Number of subjects: 240
Study 18056902 — intervention group
Group type: COMPARATOR
Intervention: No Budesonide (placebo)
Number of subjects: 240
Study 16086559 — intervention group
Group type: EXPERIMENTAL
Intervention: PTCA with provisional stenting (n = 109)
Number of subjects: 220
Study 16086559 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent (n = 111)
Number of subjects: 220
Study 11152035 — intervention group
Group type: EXPERIMENTAL
Intervention: Myopexy (Faden)
Number of subjects: 120
Study 11152035 — intervention group
Group type: COMPARATOR
Intervention: Non-Faden surgery
Number of subjects: 120
Study 9506495 — intervention group
Group type: EXPERIMENTAL
Intervention: Video self-instruction (VSI) training program for adult CPR
Number of subjects: 89
Study 9506495 — intervention group
Group type: COMPARATOR
Intervention: Traditional CPR training (American Heart Association Heartsaver course)
Number of subjects: 89
Study 7827843 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin 20 micrograms intranasal at night
Number of subjects: 33
Study 7827843 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 3044425 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg
Number of subjects: 8
Study 3044425 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 80 mg
Number of subjects: 8
Study 3044425 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 120 mg
Number of subjects: 8
Study 3044425 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31862159 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis technique
Number of subjects: 272
Study 31862159 — intervention group
Group type: COMPARATOR
Intervention: Nocebo group
Number of subjects: 272
Study 31862159 — intervention group
Group type: COMPARATOR
Intervention: Neutral group
Number of subjects: 272
Study 30261839 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.1 mg/kg intravenous bolus before anesthetic induction
Number of subjects: 40
Study 30261839 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 40
Study 28684372 — intervention group
Group type: EXPERIMENTAL
Intervention: Total body irradiation (TBI) 1320 cGy, cyclophosphamide 120 mg/kg, and fludarabine 75 mg/m2 (TCF)
Number of subjects: 100
Study 28684372 — intervention group
Group type: COMPARATOR
Intervention: Nontrial TCF regimen
Number of subjects: 100
Study 28684372 — intervention group
Group type: COMPARATOR
Intervention: Nontrial TBI-containing regimens
Number of subjects: 100
Study 28684372 — intervention group
Group type: COMPARATOR
Intervention: Nontrial chemotherapy-only regimens
Number of subjects: 100
Study 26678630 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril/β-blocker
Number of subjects: 7534
Study 26678630 — intervention group
Group type: COMPARATOR
Intervention: Placebo/β-blocker
Number of subjects: 7534
Study 23076845 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxandrolone 0.03 mg/kg per day
Number of subjects: 68
Study 23076845 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxandrolone 0.06 mg/kg per day
Number of subjects: 68
Study 23076845 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 21550084 — intervention group
Group type: COMPARATOR
Intervention: Resting energy expenditure (REE) in COPD patients
Number of subjects: 14
Study 21550084 — intervention group
Group type: COMPARATOR
Intervention: Endogenous leucine flux in COPD patients
Number of subjects: 14
Study 21550084 — intervention group
Group type: COMPARATOR
Intervention: Nonoxidative leucine disposal in COPD patients
Number of subjects: 14
Study 21550084 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between REE and endogenous leucine flux
Number of subjects: 14
Study 21550084 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between REE and nonoxidative leucine disposal
Number of subjects: 14
Study 21550084 — intervention group
Group type: COMPARATOR
Intervention: Plasma concentrations of inflammatory markers (C-reactive protein and interleukin-6)
Number of subjects: 14
Study 18355325 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin 50 mg once daily
Number of subjects: 131
Study 18355325 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study 16542769 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytosterol-ester enriched spreads
Number of subjects: 0
Study 14978854 — intervention group
Group type: EXPERIMENTAL
Intervention: Ximelagatran (36 mg twice daily)
Number of subjects: 7399
Study 14978854 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (INR = 2-3)
Number of subjects: 7399
Study 10563455 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic psychosis patients with parasuicide
Number of subjects: 704
Study 10563455 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic psychosis patients who are attempters
Number of subjects: 704
Study 10563455 — intervention group
Group type: COMPARATOR
Intervention: Chronic psychosis patients who are nonattempters
Number of subjects: 704
Study 8695563 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic surfactant treatment
Number of subjects: 304
Study 8695563 — intervention group
Group type: COMPARATOR
Intervention: Rescue surfactant treatment
Number of subjects: 304
Study 1811815 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (200 micrograms qid)
Number of subjects: 0
Study 1811815 — intervention group
Group type: COMPARATOR
Intervention: Dalargin (1 mg bid)
Number of subjects: 0
Study 1811815 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 0
Study 1811815 — intervention group
Group type: COMPARATOR
Intervention: Dalargin
Number of subjects: 0
Study 6133544 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg diazepam
Number of subjects: 5
Study 6133544 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg temazepam
Number of subjects: 5
Study 6133544 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 28658181 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous auricular cartilage
Number of subjects: 49
Study 28658181 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine acellular dermal matrix (Surgimend)
Number of subjects: 49
Study 28658181 — intervention group
Group type: EXPERIMENTAL
Intervention: Porcine acellular dermal matrix (Enduragen)
Number of subjects: 49
Study 28658181 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular cartilage
Number of subjects: 49
Study 27225607 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% povidone-iodine (group P, n=80)
Number of subjects: 160
Study 27225607 — intervention group
Group type: COMPARATOR
Intervention: Combination of 2-propanol and benzalkonium chloride (group B)
Number of subjects: 160
Study 25414318 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal rehabilitation exercise program (usual care plus guided exercise two times per week for 12 weeks, 24 sessions)
Number of subjects: 107
Study 25414318 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 107
Study 22509084 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 10 mg od
Number of subjects: 114
Study 22509084 — intervention group
Group type: COMPARATOR
Intervention: Famotidine 10 mg bid plus mosapride 5 mg tid
Number of subjects: 114
Study 20132023 — intervention group
Group type: EXPERIMENTAL
Intervention: Zuspan's scheme (1 g/h by continuous intravenous infusion)
Number of subjects: 29
Study 20132023 — intervention group
Group type: COMPARATOR
Intervention: Alternative scheme (2 g in bolus every two hours)
Number of subjects: 29
Study 18386570 — intervention group
Group type: EXPERIMENTAL
Intervention: Quxie Capsule (QXC)
Number of subjects: 40
Study 18386570 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment for cancer (chemotherapy and radiotherapy)
Number of subjects: 40
Study 15607319 — intervention group
Group type: COMPARATOR
Intervention: Calcitonin (200 IU/day)
Number of subjects: 135
Study 15607319 — intervention group
Group type: COMPARATOR
Intervention: Alendronate (10 mg/day)
Number of subjects: 135
Study 15607319 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study 12709796 — intervention group
Group type: EXPERIMENTAL
Intervention: Alveofact (SA)
Number of subjects: 0
Study 12709796 — intervention group
Group type: EXPERIMENTAL
Intervention: Poractant (SB)
Number of subjects: 0
Study 12709796 — intervention group
Group type: COMPARATOR
Intervention: Beractant (SC)
Number of subjects: 0
Study 10349523 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftibuten (10 days)
Number of subjects: 0
Study 10349523 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftibuten (15 days)
Number of subjects: 0
Study 10349523 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftibuten (20 days)
Number of subjects: 0
Study 10349523 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin-sulfisoxazole (14 days)
Number of subjects: 0
Study 8698872 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular morphine
Number of subjects: 0
Study 8698872 — intervention group
Group type: COMPARATOR
Intervention: Opioids expressed in inflamed tissue
Number of subjects: 0
Study 1960241 — intervention group
Group type: EXPERIMENTAL
Intervention: Plax pre-brushing rinse, 15 ml, rinsed twice daily for 30 seconds
Number of subjects: 10
Study 1960241 — intervention group
Group type: COMPARATOR
Intervention: Placebo rinse, 15 ml, rinsed twice daily for 30 seconds
Number of subjects: 10
Study 7346744 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (IN) 0.25 mg/kg orally for two doses, 24 hours apart
Number of subjects: 52
Study 7346744 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 6381166 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 25 mg b.i.d.
Number of subjects: 32
Study 6381166 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 50 mg b.i.d.
Number of subjects: 32
Study 29040812 — intervention group
Group type: EXPERIMENTAL
Intervention: Snacks made from buckwheat (32 g serving; 141 kcal)
Number of subjects: 38
Study 29040812 — intervention group
Group type: EXPERIMENTAL
Intervention: Pita bread made from buckwheat flour (50 g serving; 135 kcal)
Number of subjects: 38
Study 29040812 — intervention group
Group type: COMPARATOR
Intervention: Reference snack products made from corn or rice flour
Number of subjects: 38
Study 29040812 — intervention group
Group type: COMPARATOR
Intervention: Water (no-kilocalorie control)
Number of subjects: 38
Study 27081016 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 40 mg
Number of subjects: 312
Study 27081016 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin 10 mg
Number of subjects: 312
Study 23877541 — intervention group
Group type: EXPERIMENTAL
Intervention: keepin' it REAL prevention program
Number of subjects: 432
Study 23877541 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 432